At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
|Articles|May 14, 2012
FDA Puts New Limits on Oral MS Drug
Advertisement
Reacting to a death associated with the multiple sclerosis drug fingolimod (Gilenya), the FDA said patients with certain cardiac risk factors should not take the oral agent.
The death was reported last year and the agency had promised to investigate it.
In an announcement on Monday, the FDA said it still didn't know whether fingolimod caused the patient's death, but nevertheless it was adding new contraindications to the drug's label, as well as a beefed-up recommendation for monitoring patients after dosing.
Read the full story:
Source: MedPage Today
Advertisement
Related to this article
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.
A systematic review found vitamin D did not consistently reduce MS relapse rates, though some studies reported lower MRI lesion activity.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Posters in an artificial intelligence and digital care session at Kidney Week 2026 spanned CKD risk prediction and LLM-drafted prior authorization letters.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
4
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
5